BioMarin Pharmaceutical Inc. (BMRN) Cash Flow Statement

The wide variance in the OCF/NI ratio suggests that GAAP net income is a poor proxy for the company's underlying cash-generating capacity. Investors should monitor whether these fluctuations are driven by recurring revenue recognition nuances or one-time charges related to the restructuring of the gene therapy program.

The lack of a stable FCF trajectory complicates the valuation of the company's core orphan drug franchise. The recent improvement in 2026Q1 FCF margin to 26.1% may be a positive sign of cost discipline, but it remains to be seen if this level is sustainable given the ongoing competitive pressures.

These large swings in working capital appear to be tied to the timing of international tender orders, which can create artificial spikes or dips in cash flow. Analysts should look past these quarterly distortions to determine if the underlying cash conversion cycle is actually improving or merely reflecting the timing of large, infrequent payments.

While the current capital intensity appears manageable, the need for continued investment in specialized facilities may limit the company's ability to significantly expand free cash flow margins. Any further increase in CapEx/Rev would warrant investigation into whether these investments are truly growth-oriented or merely maintenance-heavy requirements for aging production assets.